| Revenue growth | Q4 revenue grew 22% QoQ to ₹736cr; FY26 revenue flat YoY. |
|---|---|
| Margins | EBITDA margins normalized to 23% in Q4 from lower prior levels. |
| Demand visibility | Demand pick-up seen from November; recovery expected to sustain into FY27. |
| Management confidence | Optimistic on volume recovery but cautious regarding West Asia conflict impact. |
Growth
Volume-led growth of 14-15% in Q4; derivatives and specialty segments now contribute 54% of revenue.
Outlook
Guided 10-12% volume growth for FY27; new CPVC and ECH capacities commissioning in Q2 FY27.
Risks
Geopolitical volatility impacting raw material costs and freight; high finance costs due to currency depreciation.
Earnings Call filed with BSE, NSE: EPIGRAL. Summary written with AI assistance from the document.
Epigral Ltd: key numbers
- Share price
- ₹1,060.60
- Market cap
- ₹4,576 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 16.9×Sector 37.5×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 1.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
- Call
- Guides 20% growth
Epigral Investor Presentation: Key Takeaways
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
- Call
- Guides 70% growth
Epigral Q1 FY27 Results: Net Profit ₹99.7 Cr, Down 38.0% YoY
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹99.7 Cr · -38.0% YoY
Epigral Earnings Call: Key Takeaways
Epigral achieved highest-ever quarterly revenue of ₹736cr in Q4FY26 with 23% EBITDA margins, driven by 15% volume growth and improved plant utilization.
Epigral Earnings Call: Key Takeaways
Epigral delivered record quarterly revenue of ₹736cr, driven by a 15% QoQ volume surge and plant stabilization after major maintenance, despite geopolitical volatility.
Epigral Earnings Call: Key Takeaways
Epigral Limited delivered record Q4FY26 revenue of ₹736 Cr (up 22% QoQ) with EBITDA margins improving to 23%. Strategy focuses on transitioning towards a 70% high-margin Derivatives & Specialty revenue mix by FY28.